

## DAFTAR PUSTAKA

- Abbas, Abul K., Lichtman, A., Pillai, S., 2015. *Basic Immunology: Functions and Disorders of the Immune System*, 5th Edition. Elsevier Health Sciences. San Francisco, California.
- Aguiar, F., Fernandez, G., Queiroga, H., Carlos, J., Cimes, L., Hespanhol, V., *et al.*, 2018. Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. *Archivos de Bronconeumología (English Edition)* 54.1 :10-17.
- Alberg, A.J., Brock, M.V., Samet, J.M., 2005. Epidemiology of lung cancer: looking to the future. *J Clin Oncol* ;23(14):3175–3185.
- Alberg, A.J., Ford, J.G., Samet, J.M., 2007. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. *Chest*, 132:29–55.
- Ali, A., Goffin, J. R., Arnold, A., Ellis, P. M., 2013. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. *Current Oncology*, 20(4), 300.
- Ambrogio, V., Pompeo, E., Elia, S., Pistolese, G.R., Mineo, T.C., 2003. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. *European journal of cardio-thoracic surgery*. 23:811–817.
- Amin, Z., Sumantri, R., Jack, Z., Alwi, I., Julius, Abdullah, M., *et al.*, 2014. *Kanker Paru*. Buku Ajar Ilmu Penyakit Dalam. Edisi Keenam. Bab 34: Onkologi Medik Khusus. Jakarta. Interna Publishing.
- Aoe, K., Hiraki, A., Kiura, K., Tabata, M., Tanaka, M., Tanimoto, M., *et al.*, 2004. Thrombocytosis as a useful prognostic indicator in patients with lung cancer." *Respiration* 71.2 : 170-173.
- Arnold, B.N., Thomas, D.C., Rosen, J.E., 2016. Lung cancer in the very young: Treatment and survival in the National Cancer Data Base. *J Thorac Oncol*, 11:1121-31.
- Arnold, M., Pandeva, N., Byrnes, G., Ezzati, M., Ferlay, J., Forman, D., *et al.*, 2015. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. *The Lancet Oncology* 16.1 : 36-46.
- Balkwill, Fran, Alberto Mantovani., 2001. Inflammation and cancer: back to Virchow?. *The lancet* 357.9255 : 539-545.
- Baratawidjaja, K.G., Rengganis, I., 2010. *Imunologi dasar*, edisi 10. Fakultas Kedokteran Indonesia. Jakarta.
- Beveridge, R., Pintos, J., Elise, M., Jerome, P., Jack, A., Siemiatycki., 2010. Lung cancer risk associated with occupational exposure to nickel, chromium VI, and cadmium in two population-based case-control studies in Montreal. *American journal of industrial medicine* 53.5 : 476-485
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 68:394–424.

- Brennan, P., Reynolds, P., Agudo, A., Pershagen, G., Benhamou, S., Merletti, F., *et al.*, 2004. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. *International Journal of cancer* 109.1 : 125-131.
- Cadranel, J., Mauguen, A., Faller, M., Zalcman, G., Daniel, C., Danton, G., *et al.*, 2012. Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2), *J Thorac Oncol.* 7: 1490–1502).
- Calle, E., Thun, M., Petrelli, J., Rodriguez, C., Health, C., 1999. Body-mass index and mortality in a prospective cohort of US adults. *New England Journal of Medicine* 341.15 : 1097-1105.
- Cedres, S., Torrejon, D., Martinez, A., Navarro, A., Zamora, E., Felip, E., *et al.*, 2012. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. *Clinical and Translational Oncology* 14.11 : 864-869.
- Chua, W., Charles, K., Baracos, V., Clarke, S., 2011. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. *British journal of cancer* 104.8 : 1288.
- Cote, M.L., Liu, M., Bonassi, S., 2012. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. *Eur J Cancer.* 48: 1957–1968.
- Dupont WD, Plummer W., 1990. Power and Sample Size Calculations: A Review and Computer Program, *Controlled Clinical Trials.* 11:116-28.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., *et al.*, 2014. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. *Int J Cancer.* 136 (5): e359-e386.
- Fischer OM, Hart S, Gschwind A, Ulrich A., 2003, EGFR signal transactivation in Cancer Cells. *Biochemical Society Transaction.* 31(6):1203-7.
- Frederick, L. G., Greene, S., Byrd, F., Compton, J., Hess, Sullivan, K., Brierley, J., *et al.*, 2002. *AJCC cancer staging manual.* Vol. 1. Springer Science & Business Media.
- Forrest, L. M., McMillan, D., McArdie, C., Angerson, W., Dagg, K., Scott, H., 2005. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. *British journal of cancer* 92.10 : 1834.
- Gama, R., Songmmath, Y., Zhangmmath, Q., Wang, J., Habbous, S., Tong, L., *et al.*, 2017. Body mass index and prognosis in patients with head and neck cancer. *Head & neck* 39.6 : 1226-1233..
- Goldstraw, P., Chansky, K., Crowley, J., 2016. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol.* 11(1):39-51.

- Go, S., Kang, M., Lee, U., Choi, H., Jo, W., Cho, Y., *et al.*, 2015. Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism. *Tumor Biology* 36.10 : 7631-7639.
- Guan, J., Zhao, W., Yang, J., Chen, Z., Huang, Z., Zhang, X., *et al.*, 2013. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. *Annals of surgical oncology* 20.4 : 1381-1388.
- Gupta, Digant, Christopher G., Lis., 2010. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. *Nutrition journal* 9.1 : 69.
- Grivennikov, Sergei I., Florian R. Greten, Michael Karin. Immunity, inflammation, and cancer. *Cell* 140.6 : 883-899.
- Hanahan, D., Robert, A., 2011. Hallmarks of cancer: the next generation. *cell* 144.5 : 646-674.
- Herbst, R.S., Heymach, J.V., Lippman, S.M., 2008. Molecular Origins of Lung Cancer. *N Eng J Med.* 359:1367-1380.
- Hexiaobo, Zhou, T., Yang, Y., Hong, S., Zhan, J., Hu, Z., *et al.*, 2015. Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. *Clinical lung cancer* 16.6 : e165-e171.
- Holgersson, G. 2017. Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC). *Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine* 1359:84 pp. Acta Universitatis Upsaliensis, Uppsala.
- Hudoyo, A., Wibawanto, A., Luthfi, A., Rima, A., Putra, A., Ratnawati, A., *et al.*, 2017. *Kanker Paru*. Pedoman Nasional Pelayanan Kedokteran. Jakarta. Kementerian Kesehatan Republik Indonesia.
- Inamura K, Ninomiya H, Ishikawa Y, Matsubara O., 2010. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? *Arch Pathol Lab Med* 134:66-72.
- Islam, KM., Jiang, X., Anggondowati, T., Lin, G., Ganti, A., 2015. Comorbidity and survival in lung cancer patients. *Cancer Epidemiology and Prevention Biomarkers*.
- Iwata, T., Inoue, K., Nishiyama, N., Morita, R., Tsukioka, T., Suehiro, S., 2007. Long-term outcome of surgical treatment for non-small cell lung cancer with comorbid liver cirrhosis. *The Annals of thoracic surgery* 84.6 : 1810-1817.
- Jafri, Syed H., Runhua Shi, Glenn, M., 2013. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. *BMC cancer* 13.1 : 158.
- Jarvholm, Bengt, Evelina., 2014. The risk of lung cancer after cessation of asbestos exposure in construction workers using pleural.
- Jian, Z., Huang, J., Nfor, O., Jhang, K., Ho, C., Lung, C., *et al.*, 2016. Pre-existing pulmonary diseases and survival in patients with stage-dependent lung adenocarcinoma: a STROBE-compliant article. *Medicine* 95.10. malignant

- mesothelioma as a marker of exposure. *Journal of occupational and environmental medicine* 56.12 : 1297.
- Karjalainen, A., Anttila, S., Vanhala, E., Vainio, H., 1994. Asbestos exposure and the risk of lung cancer in a general urban population. *Scandinavian journal of work, environment & health* : 243-250.
- Kementerian Kesehatan Republik Indonesia. 2019. Hari kanker sedunia 2019. Disadur dari <https://www.depkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html>. 28 Januari 2020.
- Khuder, S.A. 2001. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis, *Lung Cancer*. 31(2-3):139-48.
- Kurishima, K., Watanabe, H., Ishikawa, H., Satoh, H., Hizawa, N., 2017. Survival of patients with lung cancer and diabetes mellitus. *Molecular and clinical oncology* 6.6 : 907-910.
- Leung, C. C., Hui, L., Lee, R., Yew, W., Chan, R., Law, W., *et al.*, 2013. Tuberculosis is associated with increased lung cancer mortality. *The International Journal of Tuberculosis and Lung Disease* 17.5 : 687-692
- Li, N. 2015. Platelets in cancer metastasis: To help the villain to do evil. *Int J Cancer*. 138(9): 20178-2087.
- Li, W., Ma, G., Qiang, W., Deng, Y., Liu, Y., Wang, J., 2017. Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: a systematic review and meta-analysis. *Oncotarget*. 8(66): 110606–110613.
- Liu, Y., Steenland, K., Rong, Y., 2013. Exposure- response analysis and risk assessment for lung cancer in relationship to silica exposure: a 44-year cohort study of 34,018 workers. *Am J Epidemiol*. 178:1424- 1433.
- Lu, M., Chen, M., Lin, C., Tseng, Y., Huang, Y., Liu, H., *et al.*, 2017. Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study. *Thoracic cancer* 8.2 : 106-113.
- MacDonald, N. 2007. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. *J Support Oncol* 5.4 : 157-62.
- Machida, H., De Zoysa, M.Y., Takiuchi, T., Hom, M.S., Tierney, K.E., Matsuo, K., 2017. Significance of monocyte counts at recurrence on survival outcome of women with endometrial cancer. *Int J Gynecol Cancer*. 27(2): 302-310.
- Madeddu, C., Mantovani, G., Gramignano, G., 2015. *Muscle wasting as main evidence of energy impairment in cancer cachexia: Future therapeutic approaches*. *Future Oncol*, 11 : 2697-710
- Mantovani, A., Allavena, P., Sica, A., Balkwill, F., 2008. Cancer-related inflammation. *Nature* 454.7203 : 436.
- Mellemgaard, A., Luchtenborg, M., Iachina, M., 2015. Role of comorbidity on survival after radiotherapy and chemotherapy for nonsurgically treated lung cancer. *J Thorac Oncol*. 10: 272–279.
- Meza, R., Meernik, C., Jeon, J., Cote, M.L., 2015. Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. *PLoS ONE* 10(3): e0121323.
- Miller, V.A., Riely, G.J., Zakowski, M.F., 2008. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar

- carcinoma subtype, predict response to erlotinib. *J Clin Oncol.* 26:1472-1478.
- Nawrot, T., Plusquin, M., Hogervost, J., Roels, H., Cells, H., Thijt, L., *et al.*, 2006. Environmental exposure to cadmium and risk of cancer: a prospective population-based study. *The lancet oncology* 7.2 : 119-126.
- National Comprehensive Cancer Network (NCCN). 2018. Non-Small Cell Lung Cancer (Version 4.2018). [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Diakses 26 April 2018.
- Ocana, A., Nieto-Jiménez, C., Pandiella, A., Templeton, A. J., 2017. Neutrophils in cancer: prognostic role and therapeutic strategies. *Mol Cancer.* 16:137.
- Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P., 1982. Toxicity and response criteria of the eastern Cooperative oncology group. *Am J Clin Oncol.* 5:649-655.
- Ozyurek, B. A., Ozdemirel, T. S., Ozden, S. B., Erdoğan, Y., Ozmen, O., Kaplan, B., Kaplan, T., *et al.*, 2018. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non small cell lung cancer?. *The Clinical Respiratory Journal.* 12 (6) : 2013-2019.
- Paramanathan, A., Saxena, A., Morris, D.L., 2014. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. *Surg Oncol.* 23:31-39.
- Perwez Hussain, S., and Curtis C. Harris., 2007. Inflammation and cancer: an ancient link with novel potentials. *International journal of cancer* 121.11 : 2373-2380.
- Pesch, B., Kendzia, B., Wichmann, H., Gross, I., Fortes, C., Consonni, D., *et al.*, 2012. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies. *International journal of cancer* 131.5 : 1210-1219.
- Pinto, Joseph A., 2018. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. *ESMO open* 3.3 : e000344.
- Ribas, A. 2015. Releasing the brakes on cancer immunotherapy. *N Engl J Med* 373:1490-1492.
- Rosenman, K. D., Stanbury M., 1996. Risk of lung cancer among former chromium smelter workers. *American journal of industrial medicine* 29.5 : 491-500.
- Sarraf, M., Belcher, E., Raesky, E., Nicholson, A., Goldstraw, P., Lim, E., *et al.*, 2009. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. *The Journal of thoracic and cardiovascular surgery* 137.2 : 425-428.
- Sekine, Y., Behnia, M., Fujisawa, T., 2002. Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC. *Lung Cancer.* 37(1):95-101.
- Shaw, A.T., Ou, S.H., Bang, Y.J., 2014. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med.* 371:1963-1971.
- Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M. 2009. Clinical features and outcome



- of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol.* 27:4247-4253.
- Shieh, S., Probst, J., Sung, F., Tsai, W., Li, Y., Che, C., *et al.*, 2012. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes. *BMC cancer* 12.1 : 174.
- Shiroyama, T., Suzuki, H., Tamiya, A., Tanaka, A., Okamoto, N., Nakahama, K., *et al.*, 2018. Clinical characteristics of liver metastasis in Nivolumab treated patients with non small cell lung cancer. *Anticancer research*, 38:4723-4729.
- Tas, F., Ciffti, R., Kilic, L., Senem, K., 2013. Age is a prognostic factor affecting survival in lung cancer patients. *Oncology letters* 6.5 : 1507-1513.
- Temel, S., Greer, J., Muzikansky, A., Jackson, V., Dahlin, C., Lynch, T., *et al.*, 2010. Early palliative care for patients with metastatic non-small-cell lung cancer. *New England Journal of Medicine* 363.8 : 733-742.
- Thomas, A., Chen, Y., Yu, T., Jakopovic, M., Giaccone, G., 2015. Trends and characteristics of young non-small cell lung cancer patients in the United States. *Frontiers in oncology* 5:113.
- Tomita, Masaki, Takanori Ayabe, dan Kunihide Nakamura., 2017. The advanced lung cancer inflammation index is an independent prognostic factor after surgical resection in patients with non-small-cell lung cancer. *Interactive cardiovascular and thoracic surgery* 26.2 : 288-292.
- Travis, W.D., Brambilla, E., Müller-Hermelink, H.K., Harris, C., 2004. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. *WHO Classification of Tumours*. IARC Press, Lyon.
- Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., Nicholson, A.G., 2015. WHO Classification of Lung Tumours. *Journal of Thoracic Oncology*. 10(9): 1243-1260.
- Uribequerol, Eileen, Carlos R., 2015. Neutrophils in cancer: two sides of the same coin." *Journal of immunology research*.
- Visbal, L., Williams, B., Jett, J., Christine, M., Molina, J., yang, P., *et al.*, 2004. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. *The Annals of thoracic surgery* 78.1 : 209-215.
- Wang, J., Liu, Q., Yuan, S., Xie, W., Liu, Y., Xiang, Y., *et al.*, 2017. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. *Sci. Rep.* 7:8371.
- Woodard, Gavitt A., Kirk D. Jones, David M., 2016. Lung cancer staging and prognosis. *Lung Cancer*. Springer, Cham., 47-75.
- Ytterstad, Elinor, Per C. Moe, Audhild H., 2016. COPD in primary lung cancer patients: prevalence and mortality. *International journal of chronic obstructive pulmonary disease* 11 : 625.
- Zahorec, R. 2001. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratislavske lekarske listy* 102.1 : 5-14.

Zhai, R., Yu, X., Shafer, A., Wain, J., Christiani, D., 2014. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. *Chest* 145.2 : 346-353.